PE20080549A1 - 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 - Google Patents

2-fenilindoles como antagonistas del receptor de la prostaglandina d2

Info

Publication number
PE20080549A1
PE20080549A1 PE2007000951A PE2007000951A PE20080549A1 PE 20080549 A1 PE20080549 A1 PE 20080549A1 PE 2007000951 A PE2007000951 A PE 2007000951A PE 2007000951 A PE2007000951 A PE 2007000951A PE 20080549 A1 PE20080549 A1 PE 20080549A1
Authority
PE
Peru
Prior art keywords
phenyl
dichloro
indol
chloro
chlorine
Prior art date
Application number
PE2007000951A
Other languages
English (en)
Inventor
Zhaoxia Yang
Stephan Reiling
Thaddeus R Nieduzak
Rose M Mathew
Sharon Jackson
Keith J Harris
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of PE20080549A1 publication Critical patent/PE20080549A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE INDOL DE FORMULA (A), DONDE R ES R1CH2SO2-, R2CH2SO2NH-, R3NHSO2-, CICLOHEXILAMINOSULFONILO; R1 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALO; R2 ES FENILO SUSTITUIDO CON HALO; R3 ES 2,6-DICLORO-BENCILO, 3,5-DICLORO-BENCILO, 4-METOXI-FENILETILO, ENTRE OTROS; R4 ES H, 4-CLORO, 4-FLUORO, 4-METILO O 7-CLORO; R5 ES CLORO O ETILO; R6 H O METILO; R8 ES HIDROXI O -NHR7; R7 ES METILO, TETRAZOLILO, METILSULFONILO O ETILSULFONILO. SON COMPUESTOS PREFERIDOS: ACIDO{2-[4-CLORO-3-(2,6-DICLORO-BENCILSULFAMOIL)-FENIL]-1H-INDOL-3-IL}-ACETICO, ACIDO(2-{4-CLORO-3-[2-(2,4-DICLORO-FENIL)-ETILSULFAMOIL]-FENIL}-1H-INDOL-3-IL}-ACETICO, ACIDO[2-(4-CLORO-3-FENETILSULFAMOIL-FENIL)-1H-INDOL-3-IL]-ACETICO. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR DE PROSTAGLANDINA D2 Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES ALERGICAS, CHOQUE ANAFILACTICO, ACCIDENTE CEREBRO VASCULAR, ENTRE OTRAS
PE2007000951A 2006-07-25 2007-07-23 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 PE20080549A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82030206P 2006-07-25 2006-07-25
US82030106P 2006-07-25 2006-07-25
US82029906P 2006-07-25 2006-07-25

Publications (1)

Publication Number Publication Date
PE20080549A1 true PE20080549A1 (es) 2008-06-20

Family

ID=38610820

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000951A PE20080549A1 (es) 2006-07-25 2007-07-23 2-fenilindoles como antagonistas del receptor de la prostaglandina d2

Country Status (25)

Country Link
US (1) US20090176804A1 (es)
EP (1) EP2066628B1 (es)
JP (1) JP2009544721A (es)
KR (1) KR20090039735A (es)
AR (1) AR062051A1 (es)
AT (1) ATE485270T1 (es)
AU (1) AU2007276885A1 (es)
BR (1) BRPI0714554A2 (es)
CA (1) CA2659055A1 (es)
CL (1) CL2007002163A1 (es)
CO (1) CO6190511A2 (es)
CR (1) CR10577A (es)
DE (1) DE602007010010D1 (es)
DK (1) DK2066628T3 (es)
EC (1) ECSP099087A (es)
GT (1) GT200900016A (es)
IL (1) IL196587A0 (es)
MA (1) MA30643B1 (es)
MX (1) MX2009000830A (es)
NO (1) NO20090862L (es)
PE (1) PE20080549A1 (es)
PT (1) PT2066628E (es)
TN (1) TNSN08515A1 (es)
TW (1) TW200821286A (es)
WO (1) WO2008014186A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009072576A1 (ja) * 2007-12-04 2009-06-11 Sapporo Breweries Limited 骨形成促進剤
BRPI0921038A2 (pt) * 2008-11-17 2019-09-24 Hoffmann La Roche ácido naftilacéticos
BR112012024114B1 (pt) 2010-03-22 2021-02-09 Idorsia Pharmaceuticals Ltd Compostos derivados de 3-(heteroarilamino)-1,2,3,4-tetrahidro-9h-carbazol, uso dos mesmos, e, composição farmacêutica
BR112013026283A8 (pt) 2011-04-14 2018-01-30 Actelion Pharmaceuticals Ltd derivados de ácido 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indol acético e seu uso como moduladores do receptor d2 de prostaglandina
EP3382391A1 (en) 2012-10-24 2018-10-03 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
JP2015089886A (ja) * 2013-11-06 2015-05-11 国立大学法人名古屋大学 嵩高い置換基を有する化合物を用いた植物成長調整剤
SI3119779T1 (sl) 2014-03-17 2018-10-30 Idorsia Pharmaceuticals Ltd Derivati azaindolocetne kisline in njihova uporaba kot modulatorji prostaglandinskega receptorja D2
AU2015233046A1 (en) 2014-03-18 2016-11-03 Idorsia Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin D2 receptor modulators
WO2017046125A1 (en) 2015-09-15 2017-03-23 Actelion Pharmaceuticals Ltd Crystalline forms
US20200264188A1 (en) 2017-09-13 2020-08-20 Progenity, Inc. Preeclampsia biomarkers and related systems and methods
EP3759102A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759090A1 (en) * 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759078A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3759103A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
CN112384497A (zh) * 2018-05-09 2021-02-19 格卢科克斯生物科技有限公司 具有选择性nox抑制活性的新型磺酰胺衍生物
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS
CN111333516B (zh) * 2020-04-14 2022-09-06 国药集团化学试剂有限公司 一种2-氯-5-溴硝基苯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.

Also Published As

Publication number Publication date
BRPI0714554A2 (pt) 2013-05-07
AU2007276885A1 (en) 2008-01-31
CA2659055A1 (en) 2008-01-31
MA30643B1 (fr) 2009-08-03
EP2066628B1 (en) 2010-10-20
ECSP099087A (es) 2009-02-27
JP2009544721A (ja) 2009-12-17
AR062051A1 (es) 2008-08-10
US20090176804A1 (en) 2009-07-09
TW200821286A (en) 2008-05-16
GT200900016A (es) 2010-10-13
DK2066628T3 (da) 2011-02-07
CO6190511A2 (es) 2010-08-19
EP2066628A1 (en) 2009-06-10
MX2009000830A (es) 2009-02-03
DE602007010010D1 (de) 2010-12-02
ATE485270T1 (de) 2010-11-15
KR20090039735A (ko) 2009-04-22
TNSN08515A1 (en) 2010-04-14
NO20090862L (no) 2009-02-24
IL196587A0 (en) 2009-11-18
CL2007002163A1 (es) 2008-02-08
CR10577A (es) 2009-03-20
WO2008014186A1 (en) 2008-01-31
PT2066628E (pt) 2010-12-31

Similar Documents

Publication Publication Date Title
PE20080549A1 (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
CY1117085T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion
AR073898A1 (es) Compuestos de espiro-oxindol y su uso como agentes terapeuticos.
MX2008012404A (es) Derivados de amida y su aplicacion para el tratamiento de enfermedades relacionadas con proteina-g.
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
ATE540932T1 (de) Hydantoin-derivate als antibakterielle wirkstoffe
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
EA201171197A8 (ru) Замещенные производные азоантрацена, фармацевтические композиции и способы их применения
CY1112298T1 (el) Ενωσεις και μεθοδοι για ρυθμιση fxr
ATE420859T1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
PE20080186A1 (es) Derivados 4,6-disustituidos de 2-metoxi-6-etilamino-pirimidina como antagonistas del receptor de prostaglandina d2
EA201100421A1 (ru) Инсектицидные соединения
PE20131463A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
CY1113004T1 (el) Μιμητικα γλυκοκορτικοειδων, μεθοδοι κατασκευης τους, φαρμακευτικες συνθεσεις και χρησεις τους
AR076146A1 (es) Derivados de isooxazol, composicion insecticida que los comprende y su uso en metodos de control de plagas.
PE20090695A1 (es) Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
PE20130311A1 (es) Composiciones y metodos para modular la via de senalizacion de wnt
UY30339A1 (es) Acidos carboxilicos sustituidos con 4,5-difenilpirimidinilamino, procedimientos para su preparacion y su uso como productos farmacéuticos
UY30414A1 (es) Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones.
PE20070602A1 (es) Compuestos de carboxiamina como moduladores de histona desacetilasa
ATE525351T1 (de) Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung
ATE495171T1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed